Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + Pembrolizumab + Chemotherapy in Pretreated Advanced Non-squamous NSCLC with EGFR Mutations
NCT05258279Phase 2Completed
- Sponsor
- Juntendo University
- Start
- Jul 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, pembrolizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Juntendo University. Started Jul 2022; status: completed.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05258279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05258279.